Information Provided By: 
Fly News Breaks for August 22, 2019
CERS
Aug 22, 2019 | 16:30 EDT
Stephens analyst Jacob Johnson resumed coverage of Cerus with an Overweight rating and a price target of $8. The analyst says the company's pathogen reduction technology is increasingly recognized as a "vital tool" in blood safety, and he sees "numerous" catalysts on the horizon, including the final "key" guidance from the FDA on platelets next month. Johnson further cites additional potential catalysts expected in 2020 and beyond, including international opportunity for platelets along with pathogen-reduced cryoprecipitate approval in the U.S.
News For CERS From the Last 2 Days
There are no results for your query CERS
